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Uterine Fibroid Embolization
Said Izreig, Arash Fereydooni and Naiem Nassiri
Abstract
Uterine fibroids or leiomyomas are benign, hormone-dependent smooth muscle 
cell tumors that can be associated with menorrhagia, anemia, pelvic pain, urinary 
and/or intestinal symptoms, and dyspareunia. Traditionally, the mainstay of 
treatment has been surgical, consisting of hysterectomy or myomectomy. However, 
uterine artery embolization has become an increasingly utilized, minimally inva-
sive treatment modality that can be offered as either sole therapy or as a staged, 
pre-operative measure to hysterectomy. A thorough knowledge of pelvic vascular 
anatomy and facility with specific embolotherapeutic techniques are required for 
safe and effective fibroid embolization.
Keywords: uterine artery embolization, uterine fibroid, embolic agent, menorrhagia, 
internal iliac artery
1. Introduction
Uterine fibroids (UF), or leiomyomas, are benign tumors arising from uterine 
smooth muscle. UF are common with reported lifetime prevalence rates approach-
ing 70% in Caucasian women and over 80% in African American women [1]. 
Symptomatic fibroids—estimated to comprise less than 50% of all UF—are most 
commonly associated with menorrhagia and subsequent anemia in women of 
reproductive age [2]. As UF grow in volume, symptoms related to bulk effects, 
including constipation, bladder dysfunction, tenesmus, and chronic back and 
pelvic pain become problematic and may warrant intervention.
Controversy exists regarding the effect of UF on fertility. Several systematic 
reviews have reported evidence of increased rates of spontaneous abortion and 
decreased fertility [3, 4]. Because these reviews included numerous studies drawn 
from populations of women seeking reproductive assistance, the results presented 
may not be generalizable to all reproductive-aged women. A systematic review of 
studies drawn from general obstetric populations found no relation between risk of 
spontaneous abortion and presence of UF [5].
The traditional approach to UF management has been surgical. Hysterectomy 
remains the predominant intervention, with myomectomy an option for women 
desiring to maximize fertility. Uterine artery embolization (UAE) is a minimally 
invasive and uterine preserving procedure that has become an attractive therapeu-
tic alternative over the last 20 years. Its efficacy and acceptable safety profile have 
helped establish the technique as a viable approach with minimal complications for 
women interested in retaining their uterus and avoiding invasive surgery [6]. The 
procedure involves percutaneous transarterial catheterization and embolization 
of the vessels perfusing the UF in an attempt to induce ischemic necrosis of the 
culprit lesion(s).
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2. Risk factors and pathophysiology
The exact etiology of UF remains unclear. Several factors are thought to contrib-
ute to the overall risk of developing UF, including black race, nulliparity, advanced 
age prior to menopause, obesity, and hypertension [7, 8]. Menarche before age 10 
and oral contraceptive use are also associated with increased risk [7, 9]. Bleeding 
and bulk symptoms associated with UF tend to ameliorate with menopause, sug-
gesting that the persistence of UF depends on hormonal status [2]. There also exists 
a hereditary component, with first degree relatives of women affected by UF having 
a 2.5 fold higher risk of developing UF [10]. Recurrent chromosomal alterations 
and genetic mutations are found in a fraction of all UF [11, 12]. Protective factors 
include multiparity, a well-balanced diet, and progestin-only injectable contracep-
tion [7, 9, 13].
UF are classified based on their extent and location within the uterus. Broadly, 
submucosal fibroids are found immediately below the endometrium; subserosal 
fibroids beneath the serosal uterine surface; intramural fibroids within the myo-
metrium; and pedunculated fibroids are suspended from the uterus by a stalk and 
may project into the peritoneal or uterine cavities. The International Federation of 
Obstetrics and Gynecology classification system describes UF localization on an 
eight-point scale with lower values denoting closer fibroid proximity to the endo-
metrium and uterine cavity [14].
Submucosal fibroids carry an additional risk of endocavitary expulsion post-
UAE [15]. Those with larger endometrial interface to maximum dimension ratio 
are even more likely to be completely or partially expelled into the uterine cavity. In 
general, larger masses are associated with higher complications rates, although the 
majority of endocavitary masses pass with few symptoms [15]. For women whose 
UF fit the above profile and wish to undergo UAE, explaining the risk and symp-
tomatology of fibroid expulsion is essential to minimize post-procedural distress 
and ensure prompt engagement with their physician should expulsion manifest.
3. Imaging
Identification of UF is often incidental to pelvic examination or pelvic imaging. 
In patients with suggestive symptoms, trans-abdominal or trans-vaginal ultrasound 
is initially performed [16]. Color flow Doppler interrogation of the mass can help 
delineate the degree of vascularity of the UF. B-mode imaging can help delineate the 
location, depth, extent, and configuration of the UF. Further details of the uterine 
mass, including presence of potential malignancy, vascularization patterns and 
anastomoses, and the risk for passage of the infarcted mass, can be captured using 
contrast-enhanced MRI. Importantly, pre-procedural MRI provides a baseline mea-
sure of perfusion that can be tracked to measure the degree of infarction post-UAE 
[17–19]. It is important to note that imaging ought to be performed in coordination 
with a thorough gynecologic evaluation and examination including endometrial 
biopsy to rule out other etiologies. A multidisciplinary approach to patient care in 
close collaboration with colleagues in gynecology can lead to excellent outcomes [20].
4. Indications and patient selection
Asymptomatic UF discovered incidentally can generally be managed non-oper-
atively under the supervision of a gynecologist. Women experiencing symptomatic 
UF, however, are candidates for intervention and should be counseled regarding the 
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options available to them. Numerous guidelines have described the best practices 
for UAE based on reported clinical evidence [21]. A consistent picture regarding 
the ideal candidate for UAE is presented across guidelines: a patient with symptom-
atic fibroids (bleeding, pain, mass effects) who wishes to avoid invasive surgery. 
Frequently reported absolute contraindications include viable pregnancy and active 
infection [21]. Commonly cited relative contraindications include immunocom-
promised status, hostile anatomy for endovascular intervention, renal impairment, 
contrast allergy, or previous uterine surgery.
Variability exists among guidelines regarding relative contraindications. Several 
guidelines recommend considering some UF as unsuitable for UAE based on the 
relative position of the mass in the uterus; with pedunculated, submucosal and 
subserosal fibroids variably suggested as being unsuitable for UAE [21–24]. Other 
guidelines make no such recommendations regarding UF positioning, leaving the 
anatomical suitability of a patient for UAE at the discretion of the treating physician 
[21, 25]. Patient desire to retain fertility is similarly divisive. Some guidelines cite a 
small reported advantage in fertility outcomes of women treated with myomectomy 
compared to UAE as rationale for recommending against UAE in women desiring 
future fertility [26, 27]. Other studies have demonstrated similar rates of fertility 
and complications associated with pregnancy in women treated with UAE when 
compared with the general population [28, 29]. Definitive evidence regarding the 
effects of UAE on fertility remains outstanding. It is our practice to recommend 
against UAE in patients wishing to maintain fertility [20].
Larger UF measuring greater than 10 cm or large uteruses greater than 24 weeks 
were once considered contraindications to UAE based on case reports detailing poor 
outcomes in women bearing these features [30]. Continued research and experi-
ence, however, has demonstrated the safety and efficacy of UAE for treatment of 
large UF and large uteruses [31, 32]. We currently do not recommend against UAE 
based on UF or uterine size alone [20].
The determination of the best treatment approach for a given patient with UF 
should begin with a consultation that covers a complete history and physical, a 
review of OB/GYN examination and assessment, the type and degree of symptoms, 
and a review of any available imaging. Ascertaining the patient’s desire for future 
fertility and uterus preservation are important considerations in guiding interven-
tion selection. In cases where UAE is indicated, explaining the risks associated with 
the procedure, including bleeding, infection, access site complications, possible 
negative effects on fertility and the potential need for surgical reintervention and 
hysterectomy, offers the patient a full account on which to base their decision.
Though rare, other indications for UAE include abnormal placental development, 
such as placenta previa, accreta, increta, and percreta. These conditions are commonly 
treated by emergency hysterectomy and carry a high risk of intrapartum hemorrhage, 
respiratory distress syndromes, kidney failure, and death. Hybrid prophylactic bilateral 
UAE and caesarian section has been described to increase the safety of fetus delivery 
and to minimize the risk of intrapartum hemorrhage from placental detachment [33]. 
In a hybrid operating room, bilateral uterine arteries are first cannulated and the infant 
is delivered. While the umbilical cord is clamped and the vaginal cavity is packed 
with the placenta in situ, both uterine arteries are embolized. In a series of 12 patients 
who underwent UAE-assisted cesarean section, 10 patients retained their uterus and 
2 underwent hysterectomy [33]. There was no mortality, minimal blood loss and no 
post-operative infection. In these cases, the risk of low dose radiation to the fetus is 
considered negligible compared with baseline risks for all developmental abnormalities 
[34]. UAE may fall under the purview of multiple specialties, and a collaborative effort 
among gynecologists, interventional radiologists, and vascular surgeons is necessary to 
expand the availability of UAE and/or other surgical measures to more women [20].
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5. Vascular anatomy of the female pelvis
It is vital to delineate the normal vascular anatomy and its variations for prevention 
of non-target embolization. In its most common configuration (77%), the internal 
iliac artery (IIA) bifurcates into two main stems, one anterior and one posterior. Other 
modes of IIA division include three-stem in 14%, four- or more-stem in 3%, and 
one main stem in 4% of cases. The anterior division branches include the obturator, 
umbilical/superior vesical, uterine, vaginal, inferior vesical, middle hemorrhoidal, 
inferior gluteal, and internal pudendal arteries. The posterior trunk gives rise to the 
iliolumbar, the lateral sacral, and the superior gluteal arteries. The superior gluteal 
artery is invariably the terminal branch. While the iliac bifurcation and the origin 
of the IIA is best visualized under contralateral anterior oblique projection, we have 
found ipsilateral anterior oblique projections to best demonstrate the origin and course 
of the uterine artery once the IIA has been adequately accessed and catheterized [35].
The diameter of the uterine artery varies from 2 to 5 mm and is usually larg-
est during pregnancy and immediately after childbirth. It has a U-shaped course. 
It initially courses caudally against the pelvic wall, then horizontally across the 
ureter, and at last cranially along the uterus. Its three major terminal branches are 
the artery of uterine fundus, medial tubal branch, and medial ovarian artery. It 
is important to be aware of the medial ovarian branch coursing along the utero-
ovarian ligament, as it anastomoses with a branch originating from the ovarian 
artery. The medial ovarian branch provides the total ovarian supply in 4% of the 
cases. Uterine artery branches are extensively anastomosed with the contralateral 
uterine artery, as well as with the ipsilateral ovarian and the inferior epigastric 
arteries. While the uterine artery provides most of the arterial supply of the uterus, 
the ovarian artery and the artery of the round ligament also contribute [36].
UF are not fed by a specific branch, but by a peri-myomatous plexus. In the 
presence of fibroids, the branches of the uterine artery are distorted and larger in 
caliber [16]. The superficial surface of UF are usually enveloped in a dense perifi-
broid arterial plexus whereas the core of the mass remains relatively hypovascular 
[16, 37]. The ovarian arteries contribute to UF arterial supply in 5–10% of the cases, 
especially in patients who have disturbed arterial networks secondary to prior pel-
vic surgery, tubal or ovarian pathologies or a large fundal fibroid. Round ligament 
arteries and lumbar arteries are rare sources of UF perfusion. Left–right uterine 
artery anastomoses are identified in roughly 10% of patients and ovarian-uterine 
artery anastomoses in 10–30% [16]. On the contrary, pedunculated fibroids are 
generally perfused by a solitary artery coursing through the fibrotic stalk. A pro-
posed risk of necrosis and deterioration of the stalk with liberation of the mass into 
the peritoneal cavity has been used as a justification for classifying pedunculated 
fibroids as a relative contraindication to UAE [38]. Nevertheless, contrast-enhanced 
magnetic resonance imaging (MRI) of pedunculated fibroids treated with UAE 
found intact vascularization of the peduncle stalk with successful infarction of the 
mass and no complications related to UF location [38]. Other work has suggested 
that pedunculated fibroids are less likely to be completely infarcted following UAE 
although no clinical outcome data were reported [39]. The suitability of UAE in the 
treatment of pedunculated fibroids remains an outstanding issue. We currently do 
not recommend against UAE in patients with pedunculated UF configurations.
6. Choice of embolic agent
An array of embolic particles has been developed and employed in clinical prac-
tice. One of the earliest embolic materials used was non-spherical polyvinyl alcohol 
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particles (nsPVA; Merit Medical, South Jordan UT). nsPVA are non-uniform in size 
and shape and are, therefore, dependent on thrombus formation to produce complete 
occlusion of the uterine artery lumen [40]. nsPVA also tends to occlude microcath-
eters and complicate delivery. MRI assessment of UF treated with UAE using nsPVA 
frequently showed recanalization of infarcted UF in a majority of women 6 months 
post-intervention, highlighting the need for newer embolic agents suited for UAE 
[41]. Thus, spherical polyvinyl alcohol (sPVA) particles were developed to address the 
size and shape variation of nsPVA; however, in practice, sPVA particles (Contour SE 
microspheres; Boston Scientific) produced inferior improvements in symptoms and 
smaller reductions in UF size post-UAE [42].
Gelatin sponge—a biodegradable agent derived from purified gelatin—has been 
used as an embolic agent in cases of hemorrhage, and has been employed success-
fully as an embolic agent in UAE [43]. Preparing the gelatin sponge agent from the 
stock material requires hand manipulation, which produces inconsistencies in size 
and shape thereby limiting quantifiable comparisons with other more consistently 
prepared embolic agents.
Particle size influences the degree of distal embolization and potential for 
non-target embolization [31]. The observed caliber of perifibroid arterial vessels is 
between 500 and 800 μm, which justifies the typical use of calibrated particles in 
the 500–700 or 700–900 μm range [44]. Employing smaller sized particles is associ-
ated with an increased risk of uterine necrosis and should therefore be avoided [45].
Tris-acryl gelatin microspheres (TAGM; Embospheres; Merritt Medical, South 
Jordan, Utah) are calibrated microspheres that come in sizes ranging from 40 to 
1200 μm. When used for UAE, TAGM sized 500–700 μm are typically employed 
and have demonstrated distal penetration into the UF vasculature with minimal 
proximal aggregation that is observed with nsPVA [40].
A new entrant in the embolic material space is F-coated Hydrogel Microspheres 
Embozene; CeloNova BioScience, Newnan, Georgia. These microspheres are 
comprised of a hydrogel core of polymethylmethacrylate encased in a malleable 
polyphosphazene shell. These particles are biostable and are available in a range of 
sizes from 40 to 1300 μm [40]. Early experience with these agents has demonstrated 
safety and efficacy in the treatment of UF [46].
With the exception of greater symptomatic improvement with TAGM use as 
compared to sPVA, outcomes and complications of the other embolic agents gener-
ally suggests no clear evidence of superiority of TAGM [40, 42]. There is a need for 
better powered studies to differentiate among the different embolic agents.
7. Technical procedure
UAE is generally performed in a hybrid operating suite or catheterization suite 
under general or moderate sedation anesthesia. The latter requires ability and 
willingness of the patient to cooperate with positional and ventilatory instructions 
intraoperatively to maximize imaging quality as well as the accuracy of micro-
catheterization and embolic agent delivery. In the absence of contraindications, 
chemical and mechanical deep vein thrombosis prophylaxis via prophylactic dose of 
enoxaparin, graded stockings, and sequential compressive devices is administered 
before induction of anesthesia.
The single femoral artery approach is adequate to access both the ipsilateral and 
contralateral uterine arteries. The micropuncture technique is used for femoral 
arterial access. In young healthy women, clinically significant vasospasm is a serious 
consideration and must be monitored regularly. We suggest immediate availability 
of vasodilatory agents for intrarterial administration if necessary. In order to avoid 
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arterial vasospasm, some interventionalists recommend ceasing GnRH analog 
treatment several weeks before treatment [20, 35].
Over a guidewire, a 5 F multisidehole catheter of choice is advanced into 
the midabdominal aorta. Flush aortography is performed looking for pelvic 
hypervascular neoplastic changes and dilation and tortuosity of the feeding UAs. 
Contralateral obliquity of the image intensifier facilitates visualization of the ipsi-
lateral iliac bifurcation. Under roadmap guidance, selective catheterization of the 
IIA is performed using an angled guidewire and a 5 F C2 catheter (Merit Medical, 
South Jordan UT). Selective angiogram of the IIA in ipsilateral obliquity commonly 
facilitates visualization of the UA ostium. This image is then roadmapped. A coaxial 
microcatheter-based platform (Direxion; Boston Scientific, Marlborough, MA) is 
then developed over an 0.014 steerable guidewire, the tip of which can be curved 
manually before intrarterial insertion to help facilitate engagement of the target 
vessel ostium and to help overcome extreme arterial tortuosity.
Superselective microcatheterization of the UA is then performed with advance-
ment of the catheter to the proximal-most branches of the uterine artery feeding 
the fibroid. Use of power injector for angiography is essential as manual contrast 
infusion through the small caliber, high resistance microcatheter platform can 
be difficult and lead to suboptimal imaging. Once the satisfactory positioning of 
microcatheter tip is confirmed on angiography, the system is copiously flushed with 
heparinized saline in preparation for the delivery of embolic agent [20].
The embolic agent is delivered in bursts through the microcatheter under 
fluoroscopic guidance with intermittent heparin saline flush. Extreme care is taken 
to avoid reflux of the embolic agent particularly toward the end of each session 
when greater resistance to flow is encountered. The system is then gently flushed 
with heparinized saline to irrigate out the residual embolic content within the 
microcatheter. This must be performed under fluoroscopic visualization to prevent 
nontarget embolization. Adequate devascularization of the UF from the accessed 
side is then confirmed on completion angiography of the ipsilateral IIA through the 
5 F C2 catheter after removing the microcatheter coaxial platform.
Up-and-over technique is used to similarly catheterize the contralateral UA and 
deliver embolic agent as described previously. Completion aortoiliac angiogram 
is performed to ensure adequate UF devascularization and to rule out nontarget 
embolization.
Alternative techniques have been reported. Bilateral femoral puncture with 
sequential UA catheterization and simultaneous embolization is associated with 
reduced fluoroscopy time, reduced procedure time, and no added complication 
risk when compared to unilateral femoral puncture [47]. Transradial access (TRA) 
has been employed successfully in percutaneous coronary interventions for years, 
and studies exploring the suitability of TRA for UAE have been promising [48, 
49]. In those patients with sufficient collateral perfusion of the hand and suitable 
radial artery anatomy, TRA may have 100% technical success rate with no immedi-
ate complications [49]. Patients usually enjoy fewer restrictions in positioning 
and movement following the procedure and report satisfaction with the freedom 
offered by TRA.
8. Outcomes and complications
Accumulated evidence over decades has supported the use of UAE in the 
treatment of uterine masses in a safe and efficacious manner. Expected outcomes 
following UAE include a 50–60% reduction in UF size, an 88–92% reduction in bulk 
symptoms associated with UF, 90% reduction in bleeding associated symptoms, 
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and a patient satisfaction rate of 80–90% [25, 26]. Reduction in UF size can be 
visualized within weeks of UAE and continues for 3–12 months following the 
procedure. Histopathological analysis of successfully infarcted UF is characterized 
by coagulative or hyaline necrosis [50]. The degree of UF infarction as captured 
by contrast enhanced MRI 24–72 hours post-UAE has been reported to predict 
the magnitude and durability of symptomatic improvement as well as risk for 
reintervention [51]. Women exhibiting 100% infarction on post-operative imaging 
enjoyed a 0% reintervention rate after 24 months, whereas women with almost 
complete (90–99%) or partial (<90%) infarction experienced reintervention rates 
of 20 and 50%, respectively.
Interventional success is generally defined as reducing blood flow through the 
UA to near stasis and causing complete infarction of the UF [6]. Gradual revas-
cularization of the myometrium occurs in the weeks following UAE while the UF 
ideally remains infarcted and regresses. Failure rates range from 20 to 28%, most 
likely due to incomplete embolization of the UF vasculature, recanalization of the 
UF vasculature, or the persistence and engorgement of collaterals feeding the UF 
post-UAE [6, 52]. Identification of collateral blood supply to the UF, either before 
UAE using an aortogram or MRI, or peri-procedurally using cone-beam CT angiog-
raphy, will inform the embolization procedure and ensure all vessels supplying the 
UF are targeted [6, 53]. In cases where the ovarian artery is found to supply the UF, 
either independently or via a utero-ovarian anastomosis, embolization of the ovarian 
artery is required to ensure complete infarction of the UF. Despite the risk of ovarian 
compromise following ovarian artery embolization in this scenario, reports studying 
the effects of ovarian artery embolization in conjunction with UAE have found no 
evidence of menopause precipitation, nor worsening of menopausal symptoms [52]. 
This is in contrast to prior work that reported roughly 40% of women over the age of 
45 experienced ovarian failure following UAE without ovarian artery embolization 
[54]. Among women under the age of 45, no cases of ovarian failure were observed. 
These observations suggest that, should UAE negatively affect the ovarian capacity, 
the extent of ovarian function compromise is related to the patient’s age at the time 
of the procedure.
Post-embolization syndrome, involving pelvic pain, low-grade fever, nausea, 
loss of appetite, and malaise, is almost inevitable following UAE. The treatment is 
supportive, consisting of antipyretic, fluids, analgesia, and anti-inflammatory med-
ication. Over 90% of women undergoing UAE report pain following the procedure, 
making pain management an important consideration in caring for these patients 
[55]. Admitting patients for a 24-hour observation period allows for pain manage-
ment under the direct care of their physician. [20] Several approaches have been 
reported that aim to reduce post-procedural pain and opioid use in these patients. 
Peri-procedural superior hypogastric nerve block using a 0.75% ropivacaine solu-
tion is effective in minimizing post-procedural pain and significantly reduces total 
opioid usage [55]. A single pre-procedural dose of intravenous dexamethasone can 
also improve patient pain scores and reduce markers of inflammation. However, 
the total opioid use in these patients has been found not to be significantly different 
from those not receiving pre-procedural dexamethasone [56].
The most commonly reported long-term complication associated with UAE is 
permanent amenorrhea. Women over 45 years of age are reported more likely to 
experience permanent amenorrhea following UAE (20–40%) than women under 45 
(0–3%) [25]. Transient amenorrhea following UAE is often observed and may be a 
consequence of non-target ovarian artery embolization although this is not consid-
ered a major complication. Other observed complications include persistent vaginal 
discharge, transcervical expulsion of infarcted tissue, prolonged and intractable 
pain, and infection [25]. Very rare cases of deaths have been reported following 
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UAE as a result of pulmonary embolization, sepsis, and embolization of occult 
leiomyosarcoma [31].
Reintervention is indicated, should UF related symptoms return secondary to 
resumed growth of the primary UF or growth of a new UF. Reported reinterven-
tion rates range from 14 to 35% [26, 57]. Reinterventions may include repeat UAE, 
hysterectomy, or myomectomy. Patients undergoing UAE should be counseled 
regarding the risks of reintervention. Fostering long-term relationships with 
patients undergoing UAE allows for tracking of outcomes and early intervention 
should symptoms re-emerge [25].
While several guidelines cite preservation of fertility as a relative contrain-
dication to UAE, uncertainty remains regarding fertility outcomes following the 
procedure [21]. Published case series following pregnancies in women attempting to 
conceive following UAE found an overall pregnancy rate of ~30% [58]. As com-
pared to the general obstetric population, women treated with UAE have similar 
or increased rates of obstetric complications, with specifically increased rates of 
miscarriage and cesarean section deliveries [58, 59]. Notably in the majority of these 
studies, women with UF treated by UAE were older than the general obstetric popu-
lation and carried additional risk factors, which may explain some of the observed 
increases in complication rates. For women with complex UF pathology who desire 
to retain their uterus and avoid invasive surgery, UAE may be presented as an option 
that preserves some chance of conception in the future.
9. Comparison with hysterectomy and myomectomy
The traditional approach to the treatment of symptomatic fibroids has been 
surgical, with hysterectomy being the most common [60]. Complete removal of the 
uterus is a definitive treatment for UF that precludes recurrence and may be a suit-
able recommendation for women who have completed child bearing. Though rates 
of hysterectomy are decreasing, the lifetime prevalence among U.S women as of 
2012 was 45%, with nearly one-third of all hysterectomies performed as treatment 
of UF [60]. While laparoscopic hysterectomy has become more commonplace, open 
hysterectomies remain most frequently employed.
Myomectomy is a uterine sparing surgical intervention best suited to the 
removal of one to three fibroids in an anatomically accessible location [31]. Like 
hysterectomy, myomectomy may be done laparoscopic or open, with the laparo-
scopic approach associated with fewer complications and quicker recovery [61]. For 
women with submucosal fibroids projecting into the intrauterine cavity, hystero-
scopic myomectomy is a suitable option that is associated with quick recovery and 
return to daily living [2].
Laparoscopic management of UF, either by hysterectomy or myomectomy that 
employs power morcellation for specimen removal, has been associated with a risk 
of dissemination of occult sarcoma [31]. Histopathological analysis of hysterectomy 
specimens shows a 0.4% rate of unsuspected malignancy in uteruses treated for UF 
[62]. Under these circumstances, patients should be informed of the risk of occult 
malignancy dissemination.
Growing clinical experience and promise of UAE in the treatment of UF 
motivated the design and execution of several randomized clinical trials (RCTs) 
comparing medium- and long-term outcomes and patient satisfaction with UAE 
compared with surgical interventions. The embolization versus hysterectomy 
(EMMY) trial recruited women with symptomatic UF and assigned them 1:1 
to either UAE or hysterectomy [63]. Patient satisfaction rates and quality of life 
scores were similar between UAE and hysterectomy out to 10 years [64]. The study 
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reported a 69% success rate with UAE while 31% of UAE treated patients experi-
enced refractory or relapsing symptoms requiring definitive treatment by hyster-
ectomy. Of note was the observation that women with BMI >25 and a history of 
smoking at baseline were more likely to require reintervention following UAE. The 
reported 69% clinical success rate is notably lower than other reported rates rang-
ing 80–90% [31]. The authors attributed the lower UAE success rate to the fact 
that eligible candidates recruited to the study suffered severe bleeding symptoms, 
and the trial required a much longer 10-year follow-up window that is only used in 
tracking outcomes [64].
The REST trial grouped women treated with myomectomy with women treated 
with hysterectomy in order to expand the UAE comparison to surgical intervention 
[65]. Women treated with either UAE or surgery enjoyed similar satisfaction rates 
and quality of life improvements at 5 years. Differences in reintervention rates were 
noted, however, as 32% of women treated with UAE required further intervention 
within 5 years as compared to 4% of women in the surgery group. A study directly 
comparing UAE to myomectomy found symptom improvement in 88.3% of UAE 
women compared to 75.4% in myomectomy at 2 years post-intervention [66]. 
Bearing the risks of reintervention in mind, the above trials affirm UAE as a safe 
procedure that enjoys rates of satisfaction and symptom improvement similar to 
those observed in hysterectomy and myomectomy. A Cochrane review of published 
RCTs comparing UAE to surgical interventions reaffirms this view and shows that 
UAE is associated with shorter hospital stays, less disability, and similar satisfaction 
rates when compared to surgical intervention [26].
10. New generation of devices
Magnetic resonance-guided high intensity focused ultrasound (MR-g HIFU) 
is a non-invasive intervention that works to thermally ablate UF via the delivery 
focused ultrasound waves [67]. Rounds of sonification and heating lasting 30 sec-
onds are interleaved with 90-second cooling-off periods; the target tissue tempera-
tures reach 60–85°C, thereby provoking coagulative necrosis of the targeted mass 
[68]. FDA guidelines regarding MR-g HIFU limit the total and percent volumes of 
uterine mass subject to thermal ablation to confine the sonification to the fibroid. 
Prospective studies tracking symptom severity scores and quality of life indices in 
women, whose UF were treated with MR-g HIFU, found significant improvement 
of both measures after at least 2 years of follow-up [67, 68]. In a direct comparison 
with UAE, however, women who underwent MR-g HIFU reported smaller improve-
ments to quality of life scores after treatment [69]. MR-g HIFU also fared worse 
in terms of reintervention rates, with women undergoing UAE experiencing a 
6.7% reintervention rate compared to a 30% reintervention rate in the MR-g HIFU 
group at mid-term follow up [69]. Potential explanations for the different outcomes 
are that MR-g HIFU treats only a single mass whereas UAE targets all masses in 
the uterus, and that MR-g HIFU ablates only a fraction of the total mass volume 
whereas UAE completely infarcts UF.
11. Conclusion
As the rates of hysterectomy fall and patient desire for less invasive management 
of uterine fibroid rises, uterine artery embolization has become increasingly promi-
nent. Two decades of experience have validated the procedure as safe and effective 
with continued advancement in procedural techniques, equipment and imaging, 
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embolic agents, pain management, and operator experience lending to improved 
outcomes. There remain outstanding questions regarding UAE. Well-controlled 
investigations of fertility outcomes in women undergoing UAE or surgery for UF 
are needed. As new embolic agents become available, comparison trials to gauge 
efficacy and safety among the different agents are necessary. Continued delineation 
of patient anatomy that suggest susceptibility to ovarian insufficiency post-UAE 
is also important to ensure patients are well-counseled regarding their risks. The 
potential for further advancement leaves UAE well-positioned to continue its 
expansion in clinical practice.
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